Tradename: CYFENDUS
Proper Name: Anthrax Vaccine Adsorbed, Adjuvanted
Indication: Indicated for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis in persons 18 through 65 years of age when administered in conjunction with recommended antibacterial drugs.
Approval Date: 07/20/2023
Manufacturer: Emergent Product Development Gaithersburg Inc.
More: https://www.fda.gov/vaccines-blood-biologics/vaccines/cyfendus